Recent Transactions

27-May-25
$100 million
United States flag
Target: 

Emergency Care Partners

flag not available

Advised Emergency Care Partners (“ECP”), a leading provider of emergency department management services and its majority owner Varsity Healthcare Partners (“VHP”) on a growth recapitalization transaction, inclusive of a $100 million preferred equity investment led by MidOcean Partners (“MidOcean”)

17-Mar-25
Pending
$535 million
United States flag
Target: 

Notified

United Kingdom flag
Acquiror: 
Equiniti Group (a Siris Capital Group portfolio company)

Advising Equiniti Group, a Siris Capital Group portfolio company, on the acquisition of the Notified, a wholly owned subsidiary of West Technology Group., an Apollo Global Management portfolio company

11-Feb-25
$320 million (AUD value)
Australia flag
Target: 

Pacific Smiles Group

Australia flag
Acquiror: 
Genesis Capital

Advised Pacific Smiles Group Limited, one of Australia’s leading and fastest growing dental service organisations, on its response to multiple private equity proposals and ultimate sale to Genesis Capital by way of off-market takeover

04-Feb-25
Pending
$1.1 billion
United States flag
Target: 

PRISM Vision Group

United States flag
Acquiror: 
McKesson Corporation

Advising PRISM Vision Group, a leading medical eye care services company, on its majority stake sale to McKesson Corporation, a diversified healthcare services and distribution leader

12-Dec-24
$460 million
United States flag
Target: 

Brigit

United States flag
Acquiror: 
Upbound Group

Advised Upbound Group, a technology and data-driven leader in accessible and inclusive financial products that address the evolving needs and aspirations of underserved consumers, on its acquisition of Brigit, a leading financial health technology company

13-Nov-24
Pending
Undisclosed
Germany flag
Target: 

Centogene GmbH

Italy flag
Acquiror: 
Charme Capital Partners

Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of  pharmaceutical solutions and diagnostic tests for rare diseases

13-Nov-24
Pending
$12.1 billion
United States flag
Target: 

Blue Owl Technology Finance Corp. II (“OTF II”)

United States flag
Acquiror: 
Blue Owl Technology Finance Corp. (“OTF”)

Advised and provided a fairness opinion to the Special Committee of the Independent Directors of OTF II, a specialty finance company focused on originating and making loans to, and making debt and equity investment in, technology related companies, specifically software, based primarily in the US, on its merger with OTF 

30-Sep-24
Undisclosed
United States flag
Target: 

Golub Capital LLC

Japan flag
Acquiror: 
Mizuho Bank, Ltd.

Advising Mizuho Bank, Ltd., the banking arm of Mizuho Financial Group, Inc., on its purchase of a passive, non-voting minority stake in Golub Capital’s management companies

13-Aug-24
Undisclosed
Spain flag
Target: 

U.S. Operations of NextStream

United States flag
Acquiror: 
RadiusDC

Advised RadiusDC, a national owner and operator of highly-connected, urban-located data centers, on the acquistion of a series of entities comprising the U.S. operations of NextStream, a data center operator in Latin America owned by Actis

01-Jul-24
Undisclosed
United States flag
Target: 

Medical Review Institute of America

United States flag
Acquiror: 
Parthenon Capital

Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital

08-May-24
$800 million
United States flag
Target: 

U.S. Acute Care Solutions

flag not available

Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes

05-Apr-24
$820 million (AUD)
Australia flag
Target: 

illion Australia Pty Ltd

United Kingdom flag
Acquiror: 
Experian Plc

Advising Experian Plc, the world’s leading global information services company, on the acquisition of  illion Australia Pty Ltd, one of Australasia's leading consumer and commercial credit bureaus

20-Feb-24
Pending
$185 million
Australia flag
Target: 

myHomecare Group

Australia flag
Acquiror: 
Australian Unity

Advising Australian Unity on its acquisition of myHomecare Group

21-Dec-23
Undisclosed
Australia flag
Target: 

Exit of Homesafe Equity Release Joint Venture

Australia flag
Acquiror: 
Athy Pty Ltd

Adviser to Bendigo and Adelaide Bank on the exit of its investment in the Homesafe Equity Release Joint Venture

04-Oct-23
$610 million
United States flag
Target: 

Lucky Bucks, LLC

flag not available

Advised the Term Loan Ad Hoc Group to Lucky Bucks, one of the largest Class B coin operated amusement machine (“COAM”) route operators in Georgia, on Lucky Bucks’ financial restructuring and chapter 11 process

27-Sep-23
Undisclosed
United States flag
Target: 

Slayback Pharma LLC

United States flag
Acquiror: 
Azurity Pharmaceuticals

Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products

10-Aug-23
Undisclosed
United Kingdom flag
Target: 

Clinigen Ltd’s portfolio of Established Medicines

United Kingdom flag
Acquiror: 
CNX Therapeutics

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

07-Jul-23
Pending
$439 million
Australia flag
Target: 

Australian Unity Diversified Property Fund

Australia flag
Acquiror: 
Cromwell Direct Property Fund

Advising Australian Unity Property Limited, as the responsible entity of the Australian Unity Diversified Property Fund, on Australian Unity Diversified Property Fund’s merger with Cromwell Direct Property Fund

01-Jun-23
Pending
Undisclosed
United States flag
Target: 

Interest in Joint Venture with CarepathRx Health System Solutions

United States flag
Acquiror: 
The Cigna Group

Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary

25-Apr-23
Pending
Undisclosed
United Kingdom flag
Target: 

Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®

United Kingdom flag
Acquiror: 
Advanz Pharma (UK)

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

20-Mar-23
Pending
Undisclosed
Target: 

Clinigen Ltd’s Lamda Laboratories

Germany flag
Acquiror: 
Adragos Pharma

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

10-Feb-23
Pending
$415 million
United States flag
Target: 

Gaming Services Division of Global Payments

United States flag
Acquiror: 
Parthenon Capital

Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm

23-Jan-23
Pending
$200 million
United Kingdom flag
Target: 

Clinigen Ltd’s Proleukin

United States flag
Acquiror: 
Iovance Biotherapeutics

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

30-Dec-22
$153 million
United States flag
Target: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
Acquiror: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

24-Nov-22
Pending
Undisclosed
Target: 

Kyowa Kirin International’s established medicines business

Germany flag
Acquiror: 
Grünenthal

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company

Pages

show all